Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an announcement.
Shanghai Haohai Biological Technology Co., Ltd. has strengthened its senior management ranks by appointing three new deputy general managers following board and nomination committee approval on April 24, 2026. The appointments of industry veteran Ma Xianpeng, core technical leader Jiang Lixia, and subsidiary chairwoman Jin Sha reflect the company’s emphasis on production efficiency, technical quality, and subsidiary integration.
Mr. Ma brings more than 25 years of biopharmaceutical production and operations experience, including senior roles at Hunan Jingfeng Pharmaceutical and Maikoote (Suzhou) Technology. Ms. Jiang’s long tenure and technical leadership at subsidiary Shanghai Qisheng underline continuity in R&D and quality assurance, while Ms. Jin’s governance role at OHMK (Tian Jin) Medical Technology enhances coordination across the group’s medical technology business.
By broadening its deputy general manager team to three experienced insiders, Haohai is signaling a drive to reinforce operational management and corporate oversight as it scales its biopharmaceutical and medical technology operations. The expanded leadership structure may support more specialized management of production, technology, and subsidiary development, which is likely to be closely watched by employees and other stakeholders for its impact on execution and growth.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China, focusing on biological technologies and related medical products through its network of subsidiaries. The group’s operations span production, quality assurance and medical technology, positioning it within China’s fast-growing life sciences and healthcare sector.
Average Trading Volume: 156,816
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.46B
For a thorough assessment of 6826 stock, go to TipRanks’ Stock Analysis page.